Fig. 3From: Radioimmunotherapy of prostate cancer targeting human kallikrein-related peptidase 2Representation of LNCaP tumor volumes measured with caliper over 120 days after injection of a 10.1.2 MBq of 177Lu-m11B6, b 19.1.4 MBq 177Lu-m11B6, c 36 ± 0.68 MBq 177Lu-m11B6, d NaCl, e non-specific IgG 18 ± 1.3 MBq and f 30 μg m11B6Back to article page